JHL Biotech, Inc. (“JHL”, 6540. TWO) was awarded a top 20 ranking in Deloitte Touche Tohmatsu Limited’s 2017 Asia Technology Fast 500™ list. This annual ranking compares the fastest growing Asia Pacific companies in the life sciences, software and hardware tech sectors,
clean technology, media, and communications.
The company’s ranking (#19) makes it the only life sciences company and one of only two Taiwanese companies in the top 20.
JHL’s President & CEO, Racho Jordanov remarked, “We are honored and humbled to receive this recognition. That we placed atop our life sciences peers speaks for itself. But that we placed so well against great companies in industries with more modest capital requirements, yet faster growth rates, is a testament to our business model and the talent and dedication of JHL’s employees.”
About JHL Biotech
JHL Biotech Inc. is a biopharmaceutical startup founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity, and the China Development Industrial Bank. JHL Biotech’s mission is to provide the world with low-cost medicines of exceptional quality. JHL is focused on research and development of new protein-based therapies and biosimilars. JHL Biotech has two worldclass facilities built in accordance with United States, European Union, and ICH cGMP regulations and standards. For more information, please visit www.jhlbiotech.com.